Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

GPNMB Extracellular Fragment Protects Melanocytes from Oxidative Stress by Inhibiting AKT Phosphorylation Independent of CD44.

Tytuł:
GPNMB Extracellular Fragment Protects Melanocytes from Oxidative Stress by Inhibiting AKT Phosphorylation Independent of CD44.
Autorzy:
Wang Q; Department of Pigmentation Research and Therapeutics, Graduate School of Medicine, Osaka City University, Osaka 5450051, Japan.; Department of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Kuroda Y; Department of Pigmentation Research and Therapeutics, Graduate School of Medicine, Osaka City University, Osaka 5450051, Japan.; Biological Science Research Laboratories, Kao Corporation, Kanagawa 2500002, Japan.
Yang L; Department of Pigmentation Research and Therapeutics, Graduate School of Medicine, Osaka City University, Osaka 5450051, Japan.
Lai S; Department of Pigmentation Research and Therapeutics, Graduate School of Medicine, Osaka City University, Osaka 5450051, Japan.
Mizutani Y; Department of Cosmetic Health Science, Gifu Pharmaceutical University, Gifu 5011196, Japan.
Iddamalgoda A; Department of Cosmetic Health Science, Gifu Pharmaceutical University, Gifu 5011196, Japan.; Department of Research and Development, Ichimaru Pharcos Co. Ltd., Motosu, Gifu 5010475, Japan.
Guo J; Department of Pigmentation Research and Therapeutics, Graduate School of Medicine, Osaka City University, Osaka 5450051, Japan.
Yamamoto A; Department of Pigmentation Research and Therapeutics, Graduate School of Medicine, Osaka City University, Osaka 5450051, Japan.; Department of Dermatology, Graduate School of Medicine, Osaka City University, Osaka 5458585, Japan.
Murase D; Department of Pigmentation Research and Therapeutics, Graduate School of Medicine, Osaka City University, Osaka 5450051, Japan.; Biological Science Research Laboratories, Kao Corporation, Kanagawa 2500002, Japan.
Takahashi Y; Department of Pigmentation Research and Therapeutics, Graduate School of Medicine, Osaka City University, Osaka 5450051, Japan.; Biological Science Research Laboratories, Kao Corporation, Kanagawa 2500002, Japan.
Xiang L; Department of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Inoue S; Department of Cosmetic Health Science, Gifu Pharmaceutical University, Gifu 5011196, Japan.
Tsuruta D; Department of Dermatology, Graduate School of Medicine, Osaka City University, Osaka 5458585, Japan.
Katayama I; Department of Pigmentation Research and Therapeutics, Graduate School of Medicine, Osaka City University, Osaka 5450051, Japan.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Oct 07; Vol. 22 (19). Date of Electronic Publication: 2021 Oct 07.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
Oxidative Stress*
Keratinocytes/*drug effects
Melanins/*metabolism
Melanocytes/*drug effects
Melanoma/*drug therapy
Membrane Glycoproteins/*metabolism
Proto-Oncogene Proteins c-akt/*antagonists & inhibitors
Humans ; Keratinocytes/metabolism ; Keratinocytes/pathology ; Melanocytes/metabolism ; Melanocytes/pathology ; Melanoma/metabolism ; Melanoma/pathology ; Membrane Glycoproteins/genetics ; Phosphorylation ; Proto-Oncogene Proteins c-akt/genetics ; Proto-Oncogene Proteins c-akt/metabolism
References:
Exp Cell Res. 2008 Aug 1;314(13):2334-51. (PMID: 18555216)
J Cell Biochem. 2013 Dec;114(12):2729-37. (PMID: 23794283)
Onco Targets Ther. 2013 Jul 09;6:839-52. (PMID: 23874106)
J Biol Chem. 2001 Mar 16;276(11):8125-34. (PMID: 11114299)
Br J Dermatol. 2001 Jan;144(1):55-65. (PMID: 11167683)
J Cell Biochem. 2014 Jul;115(7):1243-53. (PMID: 24415158)
J Invest Dermatol. 2017 Jun;137(6):1286-1296. (PMID: 28174051)
Cancer Immunol Immunother. 2012 Feb;61(2):193-202. (PMID: 21874302)
J Dermatol. 2015 Feb;42(2):113-28. (PMID: 25622988)
Blood. 2007 May 15;109(10):4320-7. (PMID: 17284525)
Exp Dermatol. 2009 Jul;18(7):586-95. (PMID: 19320736)
Pigment Cell Melanoma Res. 2009 Feb;22(1):99-110. (PMID: 18983539)
Cell Mol Life Sci. 2016 Sep;73(17):3221-47. (PMID: 27100828)
Gene. 2008 Apr 30;413(1-2):32-41. (PMID: 18313864)
Dermatol Clin. 2017 Apr;35(2):151-161. (PMID: 28317525)
J Cell Biochem. 2001;84(1):12-26. (PMID: 11746512)
Sci Rep. 2020 Mar 18;10(1):4930. (PMID: 32188902)
Sci Rep. 2012;2:573. (PMID: 22891158)
Oncogene. 2004 Apr 12;23(16):2838-49. (PMID: 15077147)
Brain Behav. 2012 Mar;2(2):85-96. (PMID: 22574278)
J Cell Mol Med. 2018 Dec;22(12):6148-6156. (PMID: 30338917)
Oncogene. 2015 Oct;34(43):5494-504. (PMID: 25772243)
PLoS One. 2010 Aug 10;5(8):e12093. (PMID: 20711474)
Acta Neuropathol Commun. 2018 Oct 19;6(1):108. (PMID: 30340518)
J Hepatol. 2005 Apr;42(4):565-72. (PMID: 15763343)
Am J Physiol Cell Physiol. 2005 Sep;289(3):C697-707. (PMID: 16100390)
J Neuroinflammation. 2018 Mar 8;15(1):73. (PMID: 29519253)
Arch Dermatol Res. 2012 Dec;304(10):831-8. (PMID: 22871993)
J Invest Dermatol. 1997 Sep;109(3):310-3. (PMID: 9284096)
Nat Rev Dis Primers. 2015 Jun 04;1:15011. (PMID: 27189851)
PLoS One. 2012;7(8):e42955. (PMID: 22912767)
Cell Signal. 2014 Dec;26(12):2694-701. (PMID: 25173700)
Int J Mol Sci. 2018 Feb 12;19(2):. (PMID: 29439519)
J Invest Dermatol. 2014 Aug;134(8):2221-2230. (PMID: 24662764)
Sci Rep. 2016 Mar 18;6:23241. (PMID: 26988030)
J Invest Dermatol. 2008 May;128(5):1227-35. (PMID: 18037902)
Oncogene. 2003 Dec 8;22(56):8983-98. (PMID: 14663477)
J Invest Dermatol. 2003 Oct;121(4):831-6. (PMID: 14632202)
Int J Mol Sci. 2020 Dec 29;22(1):. (PMID: 33383933)
FASEB J. 2010 May;24(5):1616-29. (PMID: 20056711)
J Dermatol Sci. 2018 Feb;89(2):155-164. (PMID: 29146131)
Pigment Cell Melanoma Res. 2016 Sep;29(5):541-9. (PMID: 27223685)
J Invest Dermatol. 2007 Nov;127(11):2612-7. (PMID: 17522703)
Cancer Cell. 2008 Dec 9;14(6):458-70. (PMID: 19061837)
Contributed Indexing:
Keywords: AKT; GPNMB; oxidative stress; rhododendrol; vitiligo
Substance Nomenclature:
0 (GPNMB protein, human)
0 (Melanins)
0 (Membrane Glycoproteins)
EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
Entry Date(s):
Date Created: 20211013 Date Completed: 20211025 Latest Revision: 20211025
Update Code:
20240105
PubMed Central ID:
PMC8509362
DOI:
10.3390/ijms221910843
PMID:
34639184
Czasopismo naukowe
Glycoprotein non-metastatic melanoma protein B (GPNMB) is a type I transmembrane glycoprotein that plays an important role in cancer metastasis and osteoblast differentiation. In the skin epidermis, GPNMB is mainly expressed in melanocytes and plays a critical role in melanosome formation. In our previous study, GPNMB was also found to be expressed in skin epidermal keratinocytes. In addition, decreased GPNMB expression was observed in the epidermis of lesional skin of patients with vitiligo. However, the exact role of keratinocyte-derived GPNMB and its effect on vitiligo is still unknown. In this study, we demonstrated that GPNMB expression was also decreased in rhododendrol-induced leukoderma, as seen in vitiligo. The extracellular soluble form of GPNMB (sGPNMB) was found to protect melanocytes from cytotoxicity and the impairment of melanogenesis induced by oxidative stress. Furthermore, the effect of rGPNMB was not altered by the knockdown of CD44, which is a well-known receptor of GPNMB, but accompanied by the suppressed phosphorylation of AKT but not ERK, p38, or JNK. In addition, we found that oxidative stress decreased both transcriptional GPNMB expression and sGPNMB protein expression in human keratinocytes. Our results suggest that GPNMB might provide novel insights into the mechanisms related to the pathogenesis of vitiligo and leukoderma.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies